NCT00629759 - A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

August 31, 2007

Conditions

Neoplasms, Liver

Interventions

GENETIC

JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)

The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.

Trial Locations (1)

602-715

Dong-A University Hospital, Busan